Accelerated Partial Breast Irradiation (APBI) with Balloon Brachytherapy
Hologic’s targeted radiation therapy is a breakthrough early-stage breast cancer treatment that can offer an alternative to whole breast radiation or a mastectomy.
Balloon brachytherapy solutions directly target the lumpectomy cavity, where the cancer is most likely to recur, sparing healthy tissues and organs from the damaging effects of radiation.1-2
Hologic offers a choice between two systems: MammoSite® and Contura® systems.
MammoSite Targeted Radiation Therapy Solutions
The MammoSite system is Hologic’s legacy balloon brachytherapy system. It’s available in two configurations: single-lumen and multi-lumen catheters. The multi-lumen catheter has four offset lumens to allow for dosimetric optimization to minimize skin dose. This balloon also has a purple keyed stylet that helps you position the balloon after implantation.
Contura Multi-lumen Balloon Solutions
Contura multi-lumen balloon is a single insertion balloon brachytherapy applicator available in two sizes and two shaft configurations (standard and FLEX). With five treatment lumens, you can shift the isodose curve from the chest wall. There are two vacuum ports on the proximal and distal ends of the balloon that allow you to remove fluid or air to facilitate tissue conformance to the balloon.
Both MammoSite and Contura multi-lumen balloon brachytherapy applicators are the only single-insertion APBI technologies that meet or exceed all B-39 dosimetric guidelines.
As such, they allow you to easily satisfy the current clinical recommendation that the dose to the skin be maintained to less than 125% of the prescription dose.3-5
With seven years of positive clinical evidence, and over 90,000 women successfully treated, you can feel confident recommending this solution to your patients.2,6,8
The final analysis of the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial (N=1440) confirmed the excellent results of treatment efficacy, cosmesis and toxicity. The study also concluded that these results are similar and compared favorably with other forms of APBI and whole breast irradiation with similar follow-up period.2
- Excellent/good cosmesis was observed in:
91.3% of patients at 5 years.
90.5% of patients at 6 years.
90.6% of patients at 7 years.
- Overall rate of fat necrosis was 2.5% with an infection rate of 9.6% and few late toxicity events beyond 2 years.
- Overall symptomatic seroma rate was 13.4% and 0.6% beyond 2 years.
- Ipsilateral breast tumor recurrence (IBTR) was developed in 41 cases (2.8%) for a 5-year actuarial rate of 3.8 % (3.7% for IBC and 4.1% for DCIS).
The Five-year Results of the Initial Clinical Trial of MammoSite Balloon Brachytherapy for Partial Breast Irradiation in Early-Stage Breast Cancer involving 43 patients7 shows:
- No local recurrences.
- 83.3% of patients had good/excellent cosmetic results.
- 100% of patients would recommend MammoSite targeted radiation therapy to a friend or family member.
- 100% of patients would use MammoSite targeted radiation therapy if they had to do it over.
The safety and effectiveness of the MammoSite® radiation therapy system (RTS), MammmoSite® ML radiation therapy system and the Contura® applicator as a replacement for whole breast irradiation in the treatment of breast cancer has not been established.
More information can be found here
Women's Health Community Supported by Hologic
Comprehensive information on women’s health issues and management, management and personalisation.
Enterprise Imaging Community Supported by Agfa Healthcare
Advanced and scalable radiology solutions that can help improve care coordination, increase speed and facilitate accurate clinical decisions.
Decision Support Community Supported by Siemens Healthineers
Leading the way in highlighting useful and efficient decision support tools for improved patient outcomes.
The Omicron Variant of South Africa
The World Health Organization (WHO) declared the new Omicron variant of... Read more
Nutritional Care for Patients with COVID-19 Requiring Intensive Care
Recommendations for the management of nutrition of COVID-19 patients... Read more
JOIN OUR MANAGEMENT COMMUNITY
#RSNA2021: Hologic to Host Innovative Product Experiences and Information Sessions
Leader in women's health to showcase clinically proven solutions across... Read more
Getinge Accelerates Growth and Productivity to Reach New Financial Targets
“ Getinge ’s new financial targets for 2022-2025, an annual organic net... Read more
Johnson & Johnson to Split into Two Companies; Shares Rise
Health-care giant Johnson & Johnson is splitting off its consumer division Read more
Swiss Healthcare Provider Chooses Sectra to Improve Radiology Workflow
International medical imaging IT and cybersecurity company Sectra Read more
Expediting Heart Attack Diagnosis With Atellica VTLi Patient-Side Analyzer
Expediting triage times for patients presenting with heart attack symptoms... Read more
DMEA 2021: A week of digital health
What IT solutions are there that can help to combat the pandemic? How... Read more
Break Through Your Workflow Barriers With 3DQuorum™. Our Highest Resolution 3D™ Imaging, Faster
At Hologic , we understand the importance of reducing imaging interpretati Read more
New Fluoroscopy System From Siemens Healthineers Combines Industry-Leading Fluoroscopy & Radiography
Journées Francophones de Radiologie Diagnostique & Interventionnelle... Read more
Rainer Herzoq is Founder & Managing Partner at Digital Health Partners
Rainer Herzog is the founder and Managing Partner at Digital Health Partners.... Read more
Melissa Petrasko – New Vice President-Imaging Service Line, Central Florida Division, AdventHealth
Melissa Petrasko is the new Vice President - Imaging Service Line, Central... Read more
Dieter Zocholl- New member of the Supervisory Board at Health Proc European Association
Dieter Zocholl is now a Member of the Supervisory Board at Health Proc... Read more
Dr. Paul Wischmeyer earns prestigious FASPEN award
The American Society for Parenteral and Enteral Nutrition (ASPEN) has... Read more
John Ormiston Awarded the EuroPCR 2017 Ethica Award
The 2017 Ethica Award, the highest honour of the European cardiovascular... Read more
Gamma Medica Bolsters Executive Team to Support Fight Against Breast Cancer
Gamma Medica, a leader in molecular breast imaging (MBI) technology, announced... Read more
JOIN OUR MANAGEMENT COMMUNITY
JOIN OUR MANAGEMENT COMMUNITY